Endocrine Therapy and the Heart: What Breast Cancer Survivors Should Watch

How the agents differ

Aromatase inhibitors remove circulating oestrogen almost entirely, which is associated with rising LDL cholesterol, joint symptoms, and bone density loss. Tamoxifen has a partial oestrogen-like effect in some tissues, so lipids are often better, but venous thromboembolism risk is higher. Ovarian suppression in younger women produces an abrupt menopause with its own vascular and bone consequences.

None of these is a reason to avoid effective therapy. They are reasons to monitor different things depending on which agent is being used.

What to monitor and when

Blood pressure and a lipid profile at the start of therapy and on an agreed interval afterwards; bone density on the schedule your team recommends, particularly on an aromatase inhibitor; and weight, glucose, and activity, all of which drift over multi-year treatment.

If there was also anthracycline exposure or chest radiation, keep the cardiac surveillance schedule running in parallel rather than treating endocrine follow-up as the whole picture.

Clot risk on tamoxifen

Report calf swelling, pain, or unexplained breathlessness promptly. Flag tamoxifen use before planned surgery, prolonged immobility, or long-haul travel so that preventive measures can be discussed. Combining tamoxifen with other clot risk factors deserves an explicit conversation rather than an assumption.

Managing side effects without abandoning therapy

Joint pain, hot flushes, and fatigue drive a great deal of early discontinuation, and discontinuation costs more than the side effects usually do. Switching agent, adjusting timing, treating symptoms, and adding resistance exercise all help. Raise it with your team before stopping.